IP Library › Granted Patent US 7,565,201
Granted Patent B2
US 7,565,201 · App. 11/305,121 · Granted Jul 21, 2009

Activation of calcium-mediated cell functions in cells and tissues, including aggregation of human platelets. by nanosecond pulsed electric fields

Assignees: Eastern Virginia Medical School; Old Dominion University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,565,201
App. No.
11/305,121
Granted
Jul 21, 2009
Kind
B2
Abstract

Methods for inducing calcium mobilization in cells through the application of nanosecond pulsed electric fields (“nsPEFs”) are provided. The invention also provides a method of increasing intracellular calcium in cells through the application of nsPEFs. In one embodiment of the invention, the cells are human platelets, whereby activation and aggregation of the platelets is induced. Methods for treating an injury, trauma, or loss of blood in a subject, through the application of nsPEFs are also provided.

Claims (25)

1. A method for inducing calcium mobilization in cells comprising applying at least one nanosecond pulsed electric field (nsPEF) to the cells, whereby calcium is mobilized in said cells, wherein said at least one nsPEF has a pulse duration of at least about 100 picoseconds and no more than about 1 microsecond and an electric field strength of at least about 10 kV/cm and no more than about 350 kV/cm, wherein said cells are platelets.

2. The method of claim 1 , whereby calcium influx into said cells occurs.

3. The method of claim 1 , wherein said at least one nsPEF has a pulse duration of at least about 100 picoseconds and no more than about 1 microsecond and an electric field strength of at least about 10 kV/cm and no more than about 30 kV/cm.

4. The method of claim 1 , wherein said at least one nsPEF has a pulse duration of at least about 100 picoseconds and no more than about 1 microsecond and an electric field strength of at least about 10 kV/cm and no more than about 125 kV/cm.

5. The method of claim 1 , wherein said at least one nsPEF has a pulse duration of at least about 10 nanoseconds and no more than about 300 nanoseconds and an electric field strength of at least about 10 kV/cm and no more than about 30 kV/cm.

6. The method of claim 1 , wherein said at least one nsPEF has a pulse duration of at least about 10 nanoseconds and no more than about 300 nanoseconds and an electric field strength of at least about 10 kV/cm and no more than about 125 kV/cm.

7. The method of claim 1 , wherein said at least one nsPEF has a pulse duration of about 10 nanoseconds and an electric field strength of about 125 kV/cm.

8. The method of claim 1 , wherein said at least one nsPEF has a pulse duration of about 60 nanoseconds and an electric field strength of about 30 kV/cm.

9. The method of claim 1 , wherein at least two nsPEFs are applied.

10. The method of claim 1 , wherein at least five nsPEFs are applied.

11. The method of claim 1 , wherein at least ten nsPEFs are applied.

12. The method of claim 1 , wherein said cells are suspended in a medium.

13. The method of claim 1 , wherein said cells are included in a tissue.

14. The method of claim 2 , wherein said cells are human platelets and whereby activation and aggregation of said platelets is induced.

15. A method for increasing intracellular calcium in cells comprising applying at least one nanosecond pulsed electric field (nsPEF) to the cells, whereby intracellular calcium in said cells is increased, wherein said at least one nsPEF has a pulse duration of at least about 100 picoseconds and no more than about 1 microsecond and an electric field strength of at least about 10 kV/cm and no more than about 350 kV/cm, wherein said cells are platelets.

16. The method of claim 15 , wherein said cells are human platelets and whereby activation and aggregation of said platelets is induced.

17. A method for activating and aggregating human platelets comprising applying at least one nanosecond pulsed electric field (nsPEF) to the platelets, whereby said platelets are activated and induced to form aggregates, wherein said at least one nsPEF has a pulse duration of at least about 100 picoseconds and no more than about 1 microsecond and an electric field strength of at least about 10 kV/cm and no more than about 350 kV/cm.

18. The method of claim 17 , wherein said at least one nsPEF has a pulse duration of about 10 nanoseconds and an electric field strength of about 125 kV/cm.

19. The method of claim 17 , wherein said at least one nsPEF has a pulse duration of about 60 nanoseconds and an electric field strength of about 30 kV/cm.

20. The method of claim 17 , wherein said platelets are suspended in a medium.

21. The method of claim 17 , wherein said platelets are included in a tissue.

22. A method for treating an injury, trauma, or the loss of blood in a subject, comprising applying at least one nsPEF to platelets at the site of injury, trauma, or blood loss, whereby said platelets are activated and induced to form aggregates, wherein said at least one nsPEF has a pulse duration of at least about 100 picoseconds and no more than about 1 microsecond and an electric field strength of at least about 10 kV/cm and no more than about 350 kV/cm.

23. A method of treating an injury, trauma, or the loss of blood in a subject, comprising applying at least one nsPEF to autologous platelets, whereby said platelets are activated and induced to form aggregates, wherein said activated and aggregated platelets are applied to the site of injury, trauma, or blood loss, wherein said at least one nsPEF has a pulse duration of at least about 100 picoseconds and no more than about 1 microsecond and an electric field strength of at least about 10 kV/cm and no more than about 350 kV/cm.

24. The method of claim 22 or claim 23 , wherein said blood loss is related to a bleeding disorder resulting from inactive platelets or low platelet counts.

25. The method of claim 22 or claim 23 , wherein said blood loss is related to a platelet disorder selected from the group consisting of congenital afibrinogenemia, Glanzmann's thrombasthenia, gray platelet syndrome, and Hermansky-Pudlak syndrome.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2024
From: EASTERN VIRGINIA MEDICAL SCHOOL
To: OLD DOMINION UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 068364/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2014
From: OLD DOMINION UNIVERSITY
To: OLD DOMINION UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 033506/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2006
From: BLACKMORE, PETER F.; BEEBE, STEPHEN J.; BUESCHER, STEPHEN
To: EASTERN VIRGINIA MEDICAL SCHOOL
Reel/Frame 017729/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2006
From: SCHOENBACH, KARL H.
To: OLD DOMINION UNIVERSITY
Reel/Frame 017729/0723 →
Continuity (2)
Provisional Application 6063669500 · Dec 17, 2004
Related Publication 20060161221A1 · Jul 20, 2006